Figure 5.
(A) In contrast to other studied FLT3 inhibitors, CZT has significantly more potent activity against the Ba/F3 internal tandem duplication/F691L-mutant cell line under both medium and plasma conditions. (B) Cabozantinib potently suppressed FLT3/F691L in samples assessed with the plasma inhibitory assay. CZT indicates cabozantinib; FLT3, FMS-like tyrosine kinase 3; IC50, half-maximal inhibitory concentration; pFLT3, phosphorylated FMS-like tyrosine kinase 3.